Tizanidine Hydrochloride

CHEMBL1200329 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
290.2 g/mol
LogP
Phase
4

A hydrochloride salt form of tizanidine with the same therapeutic properties. This muscle relaxant is used to manage muscle spasticity — the tightening or stiffening of muscles — caused by conditions such as multiple sclerosis or spinal cord injury.

Berat Molekul

290,1700 g/mol

TPSA

90,40 Ų

Area Terapeutik

Mekanisme Kerja

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cl.Clc1ccc2nsnc2c1NC1=NCCN1

InChI

InChI=1S/C9H8ClN5S.ClH/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9;/h1-2H,3-4H2,(H2,11,12,13);1H

Molecular Formula

C9H9Cl2N5S

HBD / HBA

3 / 4

Ikatan yang Dapat Dirotasi

2

Atom Berat

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A hydrochloride salt form of tizanidine with the same therapeutic properties. This muscle relaxant is used to manage muscle spasticity — the tightening or stiffening of muscles — caused by conditions such as multiple sclerosis or spinal cord injury.

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Yes, Tizanidine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200329. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 114869. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.